Geron stock gains in wake of Merck deal

Shares of Geron surged this morning after the biotech announced that it had inked a collaboration deal with Merck to develop a cancer vaccine that targets telomerase. Telomerase promotes cancer growth. Details were in short supply, but Geron gains an upfront payment, milestones and a pledge by Merck to take an equity stake in its next round of venture capital.

- read this AP story for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.